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Abstract
The Disease Activity Score (DAS) is integral in tailoring the clinical management of rheumatoid arthritis (RA) patients and 
is an important measure in clinical research. Different versions have been developed over the years to improve reliability and 
ease of use. Combining the original DAS and the newer DAS28 data in both contemporary and historical studies is important 
for both primary and secondary data analyses. As such, a methodologically robust means of converting the old DAS to the 
new DAS28 measure would be invaluable. Using data from The Early RA Study (ERAS), a sub-sample of patients with both 
DAS and DAS28 data were used to develop new regression imputation formulas using the total DAS score (univariate), and 
using the separate components of the DAS score (multivariate). DAS were transformed to DAS28 using an existing formula 
quoted in the literature, and the newly developed formulas. Bland and Altman plots were used to compare the transformed 
DAS with the recorded DAS28 to ascertain levels of agreement. The current transformation formula tended to overestimate 
the true DAS28 score, particularly at the higher end of the scale. A formula which uses all separate components of the DAS 
was found to estimate the scores with a higher level of precision. A new formula is proposed that can be used by other early 
RA cohorts to convert the original DAS to DAS28.
Keywords Rheumatoid arthritis · Epidemiology · Observational studies · Statistical methods
Introduction
The Disease Activity Score (DAS) is a composite score 
developed as a means of quantifying the severity of 
rheumatoid arthritis (RA) [1]. It is central in the current 
‘treat-to-target’ (T2T) paradigm [2]. It is the most widely 
Rheumatology
INTERNATIONAL 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0029 6-018-4184-0) contains 
supplementary material, which is available to authorized users.
 * Lewis Carpenter 
 lewis.carpenter@kcl.ac.uk
 Sam Norton 
 sam.norton@kcl.ac.uk
 Elena Nikiphorou 
 enikiphorou@gmail.com
 Patrick Kiely 
 p.kiely500@btinternet.com
 David A. Walsh 
 David.Walsh@nottingham.ac.uk
 Josh Dixey 
 josh.dixey@nhs.net
 Adam Young 
 adam.young@nhs.net
1 Health Psychology Section, King’s College London, 
London, UK
2 Department of Rheumatology, King’s College London, 
London, UK
3 Department of Rheumatology, St George’s University 
Hospital NHS Foundation Trust, London, UK
4 Arthritis UK Pain Centre, University of Nottingham, 
Nottingham, UK
5 Department of Rheumatology, Wolverhampton NHS Trust, 
Wolverhampton, UK
6 Postgraduate Medicine, University of Hertfordshire, Hatfield, 
UK
2298 Rheumatology International (2018) 38:2297–2305
1 3
used ‘tool’ in clinical practice to assess and monitor the 
patients’ disease activity status and to help guide treat-
ment adjustments. In the UK, the DAS28 is one of the 
main determinants in deciding access to biologic disease-
modifying antirheumatic drugs (bDMARDs) [3].
Several versions of the DAS exist. The original DAS 
established that four measures could be combined to give 
an effective overview of the overall disease status of a 
patient: a 44 joint Swollen Joint Count (SJC), the Ritchie 
Articular Index (RAI) of 53 tender joints, the Erythro-
cyte Sedimentation Rate (ESR) and a Patient Global 
Assessment (PGA) of disease activity on a 100 mm visual 
analogue scale (VAS) [1]. A three-variable calculation 
excluding the PGA is also available. In 1995, a modified 
version of the DAS was proposed, the DAS28, which used 
counts of 28 joints for both the SJC and tender joint count 
(TJC) focusing on the hands and arms [4]. Discrepancies 
between the two DAS scoring methods has been shown to 
occur, in part, by the omission of the feet and ankles in 
the DAS28 joint count [5]. However, the DAS28 is able 
to discriminate between patients with varying levels of 
disease activity and was preferred due to its simplicity 
and feasibility in the clinical setting. Other variations of 
the DAS and DAS28 exist, including the use of C-reac-
tive protein (CRP) in place of ESR. However, the original 
four-variable DAS and DAS28 using ESR remain the most 
routinely used methods [6], and are part of the core set of 
outcomes in RA clinical trials [7].
It is agreed that the DAS and DAS28 scores cannot be 
used inter-changeably due to their differences in minimum 
and maximum values, and weighting used for each compo-
nent of the score [6]. However, comparing these data would 
provide the opportunity to study longitudinal cohorts where 
different DAS methods have been used (e.g., Norfolk Arthri-
tis Register (NOAR) [8] and the Yorkshire Early Arthri-
tis Register (YEAR) [9], along with many other registries 
worldwide [10]), and to enable meta-analyses across stud-
ies reporting different DAS outcomes. This was the case 
in early data collected from The Early RA Study (ERAS), 
which collected the three-variable DAS for patients diag-
nosed between 1986 and 2001, while the Early RA Net-
work (ERAN) collected DAS28 data for patients diagnosed 
between 2002 and 2011 [11].
Methods for transforming the original DAS to the DAS28 
metric have been proposed, and used in a number of previ-
ous studies to try and facilitate direct comparisons [11–14]. 
A commonly used formula was devised by van Gestel et al. 
in 1998 using longitudinal data from an observational cohort 
[15]. Although precise details about how the formula was 
derived are not shown, it is likely to represent a regres-
sion imputation of the original DAS regressed on DAS28 
scores to impute the missing DAS28 scores. While DAS 
and DAS28 scores are known to correlate highly, there is 
currently no research to assess the reliability and validity of 
this imputation method.
Using a sub-group of patients from the ERAS cohort 
attending one centre where both DAS and DAS28 data are 
available, this paper explores the use of imputation methods, 
including the formula given by van Gestel et al., to calculate 
missing DAS28 scores where DAS are recorded. The analy-
ses will compare levels of agreement of (1) the van Gestel 
formula, (2) univariable regression imputation using DAS 
to predict DAS28, and (3) multivariable regression imputa-
tion model using the separate components of DAS to predict 
DAS28. Finally, the paper will examine differences in trends 
over time using the different methods to calculate DAS28 to 
determine potential differences in interpretation. The aim is 
to provide a potentially more statistically reliable transfor-
mation formula for converting DAS to DAS28.
Methods
Data
The Early RA Study (ERAS) recruited a total of 1465 
patients with early RA from nine centres in England between 
1986 and 2001. All patients had a confirmed diagnosis of RA 
and were recruited within 2 years of symptom onset (median 
6-months), prior to conventional DMARD initiation. All 
patients were treated based on standard clinical practice of 
the time. Standard clinical, laboratory and radiographic data 
were collected during outpatient appointments at baseline, 
6 months, 12 months, and then yearly thereafter. Each centre 
closed to follow up at different times between 2001 and 2013 
with a maximum follow-up of 30 years (median 10 years) for 
annual outpatient follow-up. ERAS received retrospective 
ethical approval from the East Hertfordshire Local Research 
Ethics Committee in 1994 and subsequently from the Cal-
dicott Guardian.
The analysis uses a subset of the main ERAS dataset with 
data from one centre (n = 298), where the component vari-
ables for both the DAS and DAS28 were recorded for the 
same patients by the same examiner. Restricting the analyses 
to the first 5 years, the 298 patients contributed a total of 
1470 observations (mean 4.9 observations per patient).
Disease activity scores
All patients in ERAS had the 44-count SJC, the RAI, and 
ESR collected at each visit. The PGA was not routinely col-
lected by centres, so the three-variable DAS formula was 
used to calculate the original DAS for all patients [1] (Eq. 1).
(1)
DAS(3) = (0.54 × sqrt(RAI)) + 0.065 × (SJC44)
+ 0.33 × ln(ESR) + 0.22.
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For the subset of patients where the DAS28 component 
variables were collected, DAS28 was calculated using the 
four-variable formula [4] (Eq. 2)
While a PGA VAS was not routinely collected, patient 
assessment of global pain using a 0–100 VAS was. PGA 
was used where available but where missing (94% observa-
tions) the pain VAS was used in place. The large proportion 
of missing PGA data was due to the fact that PGA data was 
typically collected beyond the 5-year follow-up for patients 
recruited from this centre. Khan et al. indicates that differ-
ent measures of global health can be used inter-changeably 
without significant impact on the DAS [16]. This is likely 
due to the very high correlation between PGA and other 
measures of patient global health (i.e., PGA with pain VAS 
correlation was r = .900 in the current data). Sub-analysis 
(not shown) found that there was higher agreement between 
the DAS28 and DAS28 using pain VAS compared to just 
the three-variable DAS28 score, therefore the four-variable 
DAS28 with either the PGA or pain VAS was used.
The conversion formula given by van Gestel et al. [15] 
for imputing DAS28 based on DAS is shown in Eq. (3). The 
intention of the formula is to convert the DAS score to the 
DAS28 metric, however, it should be noted that essentially, 
as the multiplication factor is close to one, the formula sim-
ply increases the DAS score by 0.9 units.
Analysis
The analysis examines three methods of imputing DAS28. 
Whilst other imputation methods have proven more effective 
in imputing missing data, such as multiple imputation [17], 
this is typically not possible in the context of transforming 
DAS to DAS28, as no data is available for the DAS28. As 
such, this paper focuses only on the use of regression impu-
tation methods to devise a formula for wider use.
Univariable mixed-effects linear regression models 
regressed the DAS28 on to the DAS for the DAS-only 
regression imputation. Mixed models were used to account 
for the longitudinal nature of the data. The fixed effects 
from the model, the coefficient for DAS and the constant, 
were then used to calculate imputed DAS28 scores. A 
similar procedure was applied for the multivariable mixed-
effects linear regression imputation using the individual 
DAS components: the square-root of the 44-count SJC and 
the RAI, the natural logarithm of ESR and PGA/pain VAS 
scores will be used. Additionally, sex (coded male 1 and 
female 2) and age in years were also included as predic-
tors, since these are known to independently impact on 
(2)
DAS28(3) = (0.56 × sqrt(TJC28)) + (0.28 × sqrt(SJC28))
+ 0.70 ln(ESR) × 1.07 + 0.14 × PGA.
(3)DAS28 = ((1.072) × DAS) + 0.938.
ESR [18]. The coefficient of each predictor, along with 
the constant, was then used to calculate imputed DAS28 
scores. To evaluate the performance of the models, the 
model fit statistics were examined.
Mean scores of the DAS28 over the first 5 years will be 
compared to the three imputation methods outlined, and 
the mean difference, along with levels of agreement, will 
be assessed using Bland and Altman plots [19]. Bland and 
Altman plots are an effective way of assessing agreement 
between two scores and plots the difference between the 
two scores against the average of both scores. The Bland 
and Altman plots also provide summary statistics on the 
agreement between the scores using the mean difference, 
as well as providing 95% limits of agreement (LoA) around 
this mean estimate. Much like a 95% confidence interval, 
these limits are approximately 2 standard deviations above 
and below the mean difference. The closer the mean differ-
ence is to zero, the higher the agreement. The narrower the 
95% LoA, the less variation there is around this mean esti-
mate [19]. The intra-class correlation coefficient (ICC) will 
also be used as another measure of agreement between each 
imputation method and the actual DAS28 scores. Finally, 
the DAS28 will be categorised into remission, low disease 
activity (LDA), moderate disease activity (MDA) and high 
disease activity (HDA) according to the EULAR DAS28 
thresholds [20]. The proportion of patients categorised 
into each group will be assessed graphically, and agree-
ment across categories will be assessed using the Kappa 
statistic [21].
Results
Demographic data of patient sub‑sample
Of the patients from ERAS (n = 1465), 298 (20.3%) attend-
ing one centre had the component variables for both DAS 
and DAS28 collected. The 298 patients contributed 1470 
observations over 5  years (mean 4.9 observations per 
patient). Demographic and baseline clinical measures for 
the whole cohort, and those with and without DAS28 meas-
ures over the first 5 years are shown in Table 1. Patients 
with both DAS and DAS28 data were slightly older, more 
likely to be female and less likely to be seropositive. Base-
line HAQ levels were similar across the groups, however, 
patients with recorded DAS28 indicated higher levels of 
baseline DAS scores when compared to the rest of the 
cohort. This is reflected by increased SJC, RAI and pain 
VAS scores at baseline, although baseline ESR was mar-
ginally lower.
2300 Rheumatology International (2018) 38:2297–2305
1 3
Regression imputation
The fixed-effect estimates from the mixed-effects linear 
regressions for the univariable and multivariable regression 
imputations are shown in Table 2. The effect estimates give 
the following imputation formula for the univariate regres-
sion of DAS28 on DAS:
The effect estimates from the multivariable regression of 
DAS28 on the square-root 44-SJC and RAI, the log ESR, 
pain VAS, age and sex are as follows:
The estimated pseudo R2 for the univariable regression and 
multivariable regression model was 0.73 and 0.91, respec-
tively, indicating high predictive accuracy. This was further 
supported by the results of the cross-fold validations (shown 
in supplementary material 1) which indicate similar pseudo 
DAS28 = (DAS × 0.736) + 1.247.
(4)
DAS28 = (sqrt(SJC44) × 0.300) + (sqrt(RAI) × 0.175)
+ (log(ESR) × 0.739) + (PGA × 0.016)
+ (female × −0.027) + (age × −0.001)
+ − 0.086.
R2 across the models for the univariable and multivariable 
regression: 0.72 and 0.91, respectively.
Table 1  Descriptive Statistics of 
ERAS cohort with and without 
DAS data
DAS Disease Activity Score, SJC swollen joint count, RAI Ritchie Articular Index, VAS Visual Analogue 
Scale, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire
Total ERAS (DAS only) ERAS (DAS and 
DAS28)
N = 1465 N =  1167 N =  298
Age at onset (years)
 Mean (standard deviation) 55.3 (14.57) 54.62 (14.36) 57.97 (15.09)
Female, n (%) 973 (66.42%) 769 (65.90%) 204 (68.46%)
Baseline DAS
 Mean (standard deviation) 4.23 (1.63) 4.07 (1.51) 4.85 (1.91)
 Median (inter-quartile range) 4 (2) 4 (2) 5 (3)
Baseline SJC-44
 Mean (standard deviation) 17.54 (13.01) 16.1 (11.80) 23.19 (15.72)
 Median (inter-quartile range) 14 (19) 13 (18) 22 (25)
Baseline RAI
 Mean (standard deviation) 12.63 (11.11) 11.64 (10.45) 16.48 (12.69)
 Median (inter-quartile range) 10 (12) 9 (11) 14 (18)
Baseline pain VAS
 Mean (standard deviation) 43.97 (26.37) 43.61 (26.11) 45.31 (27.30)
 Median (inter-quartile range) 45 (40) 45 (38) 45 (43)
Baseline ESR
 Mean (standard deviation) 42.17 (28.79) 42.53 (28.88) 40.79 (28.42)
 Median (inter-quartile range) 37(44) 38 (44) 34 (39)
Baseline HAQ
 Mean (standard deviation) 1.15 (0.77) 1.16 (0.77) 1.1 (0.77)
 Median (inter-quartile range) 1 (2) 1 (2) 1 (2)
Seropositivity, n (%) 914 (62.39%) 744 (63.75%) 170 (57.05%)
Table 2  Regression output from univariable and multivariable regres-
sion models
DAS Disease Activity Score, SJC swollen joint count, RAI Ritchie 
Articular Index, ESR erythrocyte sedimentation rate, PGA patient 
global assessment




DAS (95% CI) 0.736 (0.71, 0.76)
SJC44 (95% CI) 0.3 (0.27, 0.33)
RAI (95% CI) 0.175 (0.14, 0.21)
ESR (95% CI) 0.739 (0.71, 0.77)
PGA (95% CI) 0.016 (0.01, 0.02)
Sex (95% CI) − 0.027 (− 0.11, 0.06)
Age (95% CI) − 0.001 (− 0.00, 0.00)
Constant (95% CI) 1.247 (1.13, 1.37) − 0.086 (− 0.31, 0.14)
Psuedo R2 0.73 0.91
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Bland and Altman plots (Fig. 1a–c) were used to inves-
tigate the level of agreement between the recorded DAS-28 
scores and each of the three imputation methods. The larg-
est bias was found for the van Gestel formula at 0.99, along 
with the widest limits of agreement (LoA) at − 1.29 to 3.27. 
The univariable regression imputation exhibited no bias 
(mean difference of − 0.00), with slightly narrower LoA at 
− 1.76–1.76, whilst the multivariable regression imputation 
also exhibited no bias (mean difference of 0.01), along with 
the narrowest LoA at − 1.02 to 1.04. The plots highlight how 
for both the van Gestel and univariable regression method, 
there is a tendency for the lower scores to be overestimated. 
Fig. 1  a–c Bland and Altman 
plots testing the agreement 
between a DAS28 score and the 
van Gestel transformation, b 
DAS28 score and the univaria-
ble method, and c DAS28 score 
and the multivariable method
Fig. 2  a–c Scatter concordance 
plots between a DAS28 score 
and the van Gestel transfor-
mation, b DAS28 score and 
the univariable method, and c 
DAS28 score and the multivari-
able method. The light grey line 
indicates the linear fit, and the 
dark grey line indicated the best 
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In fact, for both methods the minimum imputed DAS28 
score observed is approximately one. Scatter plots show-
ing concordance between each imputation method and the 
DAS28 score are shown in Fig. 2a–c. The red line is the 
reduced major axis of the data, which is equivalent to the 
slope of the correlation between the variables. The blue line 
shows the best fitting (non-linear) fractional polynomial line. 
This also highlights how both the van Gestel and univariable 
method overestimate true DAS28 scores at the lower and 
higher end of the scale, whereas the multivariable method 
indicates much closer agreement across the whole range of 
the score.
The Pearson correlation between the DAS28 and van 
Gestel formula was 0.85, for the univariable regression was 
0.85 and for the multivariable regression was 0.95. The ICC 
for the transformation formula was the lowest at 0.72 (95% 
confidence interval 0.69–0.74), followed by the regression 
imputation using only the DAS at 0.84 (95% CI 0.83–0.86), 
and finally the highest ICC was observed for the multiple 
regression imputation with the component scores at 0.95 
(95% CI 0.95–0.96).
When categorised into remission, LDA, MDA and HDA, 
the recorded DAS28 scores indicated 22% of scores in 
remission, 12% of scores in LDA, 38% of scores in MDA 
and 28% of scores in HDA. The van Gestel formula saw an 
increased proportion of scores recorded as HDA at 45%, 
with lower proportions in the other groups. Conversely, both 
the univariable imputation and the multivariable imputation 
indicated slight underestimation in the remission and HDA 
categories, and slight overestimation in the LDA and MDA 
categories.
The weighted Kappa agreement analysis of the DAS28 
categories indicated the highest level of agreement between 
the multivariable imputation at 97.6% and a Kappa statistic 
of 0.91. Univariable imputation using only the DAS score 
indicated an agreement of 95.2%, with a Kappa statistic of 
0.81, whilst the transformation formula method indicated 
the lowest agreement at 93.6% and a Kappa statistic of 0.77.
DAS imputations over time
The overall mean of the DAS28 over the first 5 years was 
4.10 (SD 1.7). This compared to an overall mean of 5.09 (SD 
2.19) using the van Gestel formula, 4.10 (SD 1.51) using 
univariable regression imputation of DAS and 4.11 (SD 
1.63) using the multivariable regression imputation with the 
separate DAS components. While the mean scores were sim-
ilar for the univariable and multivariable regression scores, 
the variability in the DAS28 was better approximated by 
the multivariable imputation model. The mean and standard 
deviations for each method over 5 years follow-up is given 
in Table 3. Figure 3 indicates the mean scores, along with 
the 95% confidence interval of the DAS28, the van Gestel 
formula, the univariable imputation and the multivariable 
imputation.
Discussion
Using a sub-sample of early RA patients from a longitudi-
nal cohort, this study found that multivariable regression 
imputation of the DAS28 using the separate components 
of the original DAS measure resulted in the highest level of 
agreement when compared with recorded DAS28 scores. 
Furthermore, using the formula provided by van Gestel et al. 
[15], resulted in the lowest levels of agreement in this data-
set. Whilst univariable regression imputation using only the 
total DAS score provided an improvement over the formula 
provided by van Gestel et al. [15], it showed similar levels 
of variability in the agreement when compared to the van 
Gestel transformation formula, across the spectrum of low 
to high scores.
Table 3  Mean (SD) of the recorded DAS28 score, along with the transformed DAS28 score using the van Gestel formula, univariable imputa-
tion and multivariable imputation
DAS Disease Activity Score
Total Baseline 1 year 2 years 3 years 4 years 5 years
N =1499 N = 295 N = 237 N = 257 N =243 N =237 N =230
DAS28
 Mean (standard deviation) 4.1 (1.70) 5.06 (1.45) 3.79 (1.53) 3.73 (1.57) 3.86 (1.77) 3.93 (1.79) 4.04 (1.72)
DAS28 van Gestel formula
 Mean (standard deviation) 5.09 (2.19) 6.14 (2.05) 4.69 (1.96) 4.63 (2.11) 4.89 (2.21) 4.94 (2.23) 5.01 (2.22)
DAS28 univariable imputation
 Mean (standard deviation) 4.1 (1.51) 4.82 (1.41) 3.82 (1.35) 3.78 (1.45) 3.96 (1.52) 3.99 (1.53) 4.04 (1.53)
DAS28 multivariable imputation
 Mean (standard deviation) 4.11 (1.63) 5.03 (1.34) 3.84 (1.49) 3.78 (1.58) 3.89 (1.71) 3.89 (1.67) 3.98 (1.64)
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The relatively large improvement in the mean difference 
between the univariable regression imputation using the 
total DAS in this analysis, compared to the formula by van 
Gestel et al. [15] suggests that using regression imputation 
formulae from different datasets may lead to some bias in the 
calculation of the transformed scores. Over the course of the 
first 5 years, the DAS28 using this formula was consistently 
more than one unit greater than the true DAS28 score, which 
resulted in much higher proportion of patients categorised 
into the HDA group. It is unclear why the univariable regres-
sion imputation devised using the ERAS data differed quite 
so significantly from the formula by van Gestel et al. [15], 
but it may be in part due to fundamental differences between 
the patient populations, such as differences between Dutch 
and UK patients, disease duration or disease severity that 
have impacted on the correlation between the two variables. 
Thus, ERAS is a cohort of patients with newly diagnosed 
RA where the components of the DAS will be less influ-
enced by damage as would become apparent in patients with 
more longstanding disease. Unfortunately, the details of the 
derivation of the van Gestel formula are not clear, making it 
impossible to interrogate fully.
The analyses demonstrated that performing multivari-
able regression imputation using the separate components 
of DAS within the same dataset is the best approach for 
transforming DAS to DAS28. This is useful in situations 
where the DAS has been recorded but the DAS28 is pre-
ferred. Such instances include longitudinal studies consid-
ering secular trends over time [11, 14] and meta-analyses 
[22, 23]. In such instances, where the DAS components are 
known, the authors recommend the use of the multivariable 
regression imputation formula outlined in this analysis in 
datasets of early RA, as this demonstrated greater agreement 
when compared to the van Gestel formula or the use of the 
univariable regression imputation formula.
Other forms of imputation, such as multiple imputation 
using chained equations (MICE) are also available, that have 
been shown to be less biased and more robust in imput-
ing missing data [17]. Sensitivity analysis using a MICE 
approach was conducted (results not shown), however, it 
was not found to have worse levels of agreement compared 
to the multivariable regression imputation method outlined. 
This is to be expected since MICE treats the DAS28 score 
as unobserved, which introduces Monte Carlo error into 
the estimates. Given the additional steps involved in the 
calculation and use of MICE and multiply imputed data, 
the authors recommend that it should only be used in cases 
where individual components of the DAS28 are missing, to 
allow for more complete calculation of the DAS28 measure. 
In such cases, it is important that a measure of uncertainty 
around the imputation estimates is also given. However, 
for instances where only the original DAS is measured, the 
multivariable regression imputation method and formula 
outlined can be used.
Examination of demographic and baseline clinical vari-
ables for the sub-sample of patients with both DAS and 
DAS28 data indicated that, on average, these patients had 
higher disease activity at presentation. This could there-
fore indicate that the imputations were based on a sub-
group of patients with more severe forms of RA. Interest-
ingly, incidence of seropositivity and levels of ESR were 
lower than the rest of the cohort, suggesting that higher 
Fig. 3  Mean and 95% Confi-
dence Intervals over the first 
5-years of the van Gestel trans-
formation, univariable method 
and multivariable method, 
along with the recorded Disease 
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DAS may have been influenced more by TJC and pain 
VAS, the so-called subjective markers, rather than the 
more objective markers of inflammation [23, 24]. Nev-
ertheless, it does suggest that these patients from which 
the multivariable regression imputation was derived, rep-
resent a marginally different sub-type of RA at presenta-
tion. Furthermore, the use of the pain VAS rather than the 
PGA VAS score for the majority of the DAS28 scores may 
have influenced the results. However, previous research 
has demonstrated that different measures of global health 
can be used interchangeably without significant impact 
on the DAS measure [16]. This, along with the very high 
agreement between the pain VAS and PGA VAS suggests 
that any bias is likely to be low from adopting this method. 
Moreover, this study represents the first analysis to inves-
tigate the use of different DAS scores in RA using one of 
the largest datasets of early RA patients, with long-term 
follow-up.
In summary, the analysis presented demonstrates the 
advantage of using multivariable regression imputation 
in situations where older data using DAS are to be con-
verted to DAS28, to facilitate aggregation of data. While 
the best method is to use estimates from a regression 
model derived from the data itself, the paper provides a 
formula to transform data based on the separate compo-
nents of the DAS, rather than just the overall DAS itself, in 
instances where data-specific parameters are not available. 
This formula provides an improved and statistically more 
reliable method for converting DAS to DAS28 for long-
term analysis where research necessitates the combination 
of historical and contemporary data in RA.
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